14. LIFE BELOW WATER

Stifel Nicolaus Lowers Zoetis (NYSE:ZTS) Price Target to $225.00 – Defense World

Written by Amanda

Zoetis (NYSE:ZTSGet Rating) had its price target decreased by Stifel Nicolaus from $275.00 to $225.00 in a research report sent to investors on Friday, The Fly reports.

Several other research firms also recently commented on ZTS. Citigroup lowered their price objective on shares of Zoetis from $232.00 to $208.00 and set a neutral rating for the company in a research note on Wednesday, March 9th. StockNews.com cut shares of Zoetis from a strong-buy rating to a buy rating in a report on Tuesday, April 26th. Finally, The Goldman Sachs Group reduced their target price on shares of Zoetis from $237.00 to $208.00 and set a buy rating for the company in a report on Thursday, May 19th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Zoetis presently has a consensus rating of Moderate Buy and a consensus target price of $229.75.

NYSE:ZTS opened at $174.61 on Friday. Zoetis has a 12 month low of $154.18 and a 12 month high of $249.27. The firm has a fifty day simple moving average of $168.99 and a 200-day simple moving average of $192.21. The company has a current ratio of 2.25, a quick ratio of 1.58 and a debt-to-equity ratio of 1.12. The company has a market capitalization of $82.18 billion, a P/E ratio of 40.05, a PEG ratio of 2.76 and a beta of 0.77.

Zoetis (NYSE:ZTSGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.22 by $0.10. Zoetis had a net margin of 26.27% and a return on equity of 49.62%. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.98 billion. During the same period in the previous year, the firm posted $1.26 earnings per share. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. Equities analysts forecast that Zoetis will post 5.05 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Thursday, July 21st will be issued a $0.325 dividend. The ex-dividend date is Wednesday, July 20th. This represents a $1.30 dividend on an annualized basis and a yield of 0.74%. Zoetis’s payout ratio is 29.82%.

In other news, Director Willie M. Reed sold 1,855 shares of the business’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $162.31, for a total transaction of $301,085.05. Following the completion of the sale, the director now owns 6,782 shares of the company’s stock, valued at $1,100,786.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 2,167 shares of the business’s stock in a transaction dated Tuesday, April 26th. The stock was sold at an average price of $178.96, for a total transaction of $387,806.32. Following the sale, the executive vice president now directly owns 23,687 shares of the company’s stock, valued at approximately $4,239,025.52. The disclosure for this sale can be found here. 0.12% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the company. Horizon Investments LLC increased its stake in shares of Zoetis by 5.5% during the fourth quarter. Horizon Investments LLC now owns 9,113 shares of the company’s stock worth $2,220,000 after purchasing an additional 477 shares in the last quarter. Garrett Investment Advisors LLC acquired a new position in Zoetis during the fourth quarter worth about $433,000. Mn Services Vermogensbeheer B.V. boosted its position in Zoetis by 1.9% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 362,603 shares of the company’s stock worth $88,486,000 after acquiring an additional 6,800 shares during the last quarter. Freedom Day Solutions LLC boosted its position in Zoetis by 0.9% during the fourth quarter. Freedom Day Solutions LLC now owns 10,258 shares of the company’s stock worth $2,503,000 after acquiring an additional 92 shares during the last quarter. Finally, Ensign Peak Advisors Inc boosted its position in Zoetis by 13.9% during the fourth quarter. Ensign Peak Advisors Inc now owns 278,020 shares of the company’s stock worth $67,845,000 after acquiring an additional 33,950 shares during the last quarter. 90.73% of the stock is owned by institutional investors and hedge funds.

About Zoetis (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More

Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai